1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
"Small Business Innovation Research (SBIR) / Small Business Technology Transfer (STTR) Program" is currently closed and not accepting applications.
Small Business Innovation Research (SBIR) / Small Business Technology Transfer (STTR) Program is sponsored by National Institutes of Health (NIH). The NIH SBIR and STTR grant funding opportunities offer small business entrepreneurs non-dilutive funding for early-stage research and development in health-related areas. Applications are accepted three times a year.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs | NCCIH NIH Websites Are Changing U.S. Department of Health and Human Services National Institutes of Health Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs Get Weekly Emails or the Semimonthly NCCIH Update e-Newsletter NCCIH’s Small Business Program The National Center for Complementary and Integrative Health (NCCIH) offers two distinct funding mechanisms that advance small businesses: The Small Business Innovation Research (SBIR) program The Small Business Technology Transfer (STTR) program Together, these programs are known as America’s Seed Fund.
The SBIR and STTR programs are one of the largest sources of early-stage capital for technology commercialization in the United States. Both programs allow U.S.-owned and -operated small businesses to engage in Federal research and development that has a strong potential for commercialization.
The National Institutes of Health’s (NIH) SBIR and STTR programs invest over 1 billion dollars each year into health and life science companies that are creating innovative technologies that align with NIH’s mission to improve health and save lives. A key objective is to translate promising technologies to the private sector and enable lifesaving innovations to reach consumer markets.
You can search for examples of projects currently funded by NCCIH by using NIH RePORTER . Understanding the SBIR/ STTR Programs Both the SBIR and STTR programs are divided into the three phases listed below. NIH has special Technical Assistance Programs to help small businesses move their technologies from the lab into the hands of customers.
The NIH Niche Assessment Program and the I-Corps at NIH program are for Phase I awardees, and the NIH Commercialization Accelerator Program is for Phase II or Phase IIB awardees. Phase I: Feasibility and Proof of Concept.
The objective of Phase I is to establish the technical merit, feasibility, and commercial potential of the proposed research/research and development (R/R&D) efforts and to determine the quality of performance of the small business awardee organization prior to providing further Federal support in Phase II. Click on “See More” below to view NCCIH-Specific Budget and Duration Policies. Phase II: Research/Research and Development.
The objective of Phase II is to continue the R/R&D efforts initiated in Phase I. Funding is based on the results achieved in Phase I and the scientific and technical merit and commercial potential of the project proposed in Phase II. Only Phase I awardees are eligible for a Phase II award.
Click on “See More” below to view NCCIH-Specific Budget and Duration Policies. Phase III: Commercialization. The objective of Phase III, where appropriate, is for the small business to pursue commercialization objectives resulting from the Phase I/II R/R&D activities.
The NIH SBIR/STTR programs do not fund Phase III, and NIH does not generally provide any Phase III funding to small businesses.
NIH also has a Fast-Track application that allows small businesses to submit one application for Phase I and Phase II, a Direct SBIR Phase II solicitation that permits small businesses to bypass a Phase I award if they have already proved the feasibility of their technology, and a Commercialization Readiness Pilot Program solicitation that can help support commercialization activities.
For more information about which solicitation is best suited for your small business, view the Funding page and speak to the appropriate SBIR/STTR program manager . NCCIH Participation in Fast-Track: NCCIH does not participate in the Fast-Track option through NCCIH-issued SBIR/STTR Funding Opportunity Announcements (FOAs).
If interested in pursuing a Fast-Track option via the Omnibus solicitations, please contact a member of the NCCIH SBIR/STTR team.
As listed in NOT-AT-20-017 , “NCCIH Policy Change to Budget Limit and Grant Durations for SBIR/STTR Phase I and Phase II Applications,” for budgetary, administrative or programmatic reasons, NCCIH may decide not to fund an application or may decrease the length of an award and/or the budget recommended by a review committee.
Through this Notice, NCCIH has revised its budget and duration policies for SBIR/STTR Phase I and Phase II applications. Generally, NCCIH will not fund: Phase I applications greater than $256,580 total costs for the duration of the project or project periods greater than 2 years. Phase II applications greater than $1,710,531 total costs for the duration of the project or project periods greater than 3 years.
For “ National Institutes of Health SBA-Approved SBIR/STTR Topics for Awards Over Statutory Budget Limitations ,” the Small Business Administration (SBA) has approved an NIH SBIR/STTR Topic Waiver list for which NCCIH generally will not fund: Phase I applications greater than $325,000 total costs per year or project periods greater than 2 years.
Phase II applications greater than $2,000,000 total costs for the duration of the project or project periods greater than 3 years. How To Apply: Step-By-Step Instructions This interactive infographic from the NIH SEED website provides step-by-step instructions on how to apply for SBIR and STTR grants. Click to view the full infographic .
According to the current listing, eligibility includes: Small business entrepreneurs with innovative research and development projects relevant to the NIH mission. Most applications are submitted to parent announcements, but specific opportunities for targeted research areas also exist. Confirm the full requirements in the official notice before applying.
The most recent published deadline was April 5, 2005, which has passed. This is an annual program, so a new cycle should follow. Check the funder's website for the next application window.
Small Business Innovation Research (SBIR) / Small Business Technology Transfer (STTR) Program is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
Past winners and funding trends for this program
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article